University of Nebraska–Lincoln Develops Adaptable DNA Vaccine Platform to Strengthen Swine Influenza Control

Scientists at the University of Nebraska–Lincoln have introduced a next-generation DNA vaccine platform designed to improve the prevention of swine influenza while reducing manufacturing costs and accelerating vaccine development. 

Reported in npj Vaccines, the research describes a system that uses lipid nanoparticles to transport DNA into pig muscle cells, enabling the animals to produce protective immune responses within one to two weeks after a single administration. 

The platform achieved strong antibody production and demonstrated improved protection against influenza infection compared with earlier DNA vaccine approaches. 

An additional benefit is its safety profile, as it did not trigger the respiratory complications that are sometimes associated with conventional inactivated influenza vaccines when animals encounter different viral strains. 

The technology is built as a flexible platform that can be quickly modified by replacing its synthetic genetic sequence, allowing new vaccine candidates to be produced in roughly one month without handling live influenza viruses. 

Beyond swine health, researchers are exploring its application for poultry and other livestock diseases. 

The innovation has the potential to strengthen disease control, enhance outbreak preparedness, and provide livestock producers with a practical, scalable, and cost-efficient vaccination strategy.